{"id":"ebeb651c5720","type":"article","url":"https://hartvaat.nl/2021/04/01/sglt2-remmers-bij-hfref-meta-analyse-van-vier-effectmodificatoren/","title":"SGLT2-remmers bij HFrEF: meta-analyse van vier effectmodificatoren","title_en":"Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"ESC heart failure","doi":"10.1002/ehf2.13241","source_url":"https://doi.org/10.1002/ehf2.13241","authors":["Mei Qiu","Liang-Liang Ding","Ze-Lin Zhan","Hai-Rong Zhou"],"significance":7,"published":"2021-04-01","source_date":"2021-04-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis examined four factors (diabetes status, baseline eGFR, NT-proBNP, and blood pressure) that may modify the efficacy of SGLT2 inhibitors in HFrEF, finding consistent benefit across all subgroups.","created":"2026-07-03T10:29:07Z","updated":"2026-07-03T13:28:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse naar de effecten van vier factoren op de werkzaamheid van SGLT2-remmers bij HFrEF.","abstract_original":""}